These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9687379)

  • 21. LB11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus.
    Vouillamoz J; Entenza JM; Hohl P; Moreillon P
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4322-7. PubMed ID: 15504859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
    Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
    FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Occurrence of quinolone resistance in Staphylococcus aureus from nosocomial infection.
    Witte W; Grimm H
    Epidemiol Infect; 1992 Dec; 109(3):413-21. PubMed ID: 1468526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis.
    Entenza JM; Hohl P; Heinze-Krauss I; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2002 Jan; 46(1):171-7. PubMed ID: 11751129
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.
    Bonilla HF; Zarins LT; Bradley SF; Kauffman CA
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):17-21. PubMed ID: 8950524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus.
    Kojima T; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1123-7. PubMed ID: 2393270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus.
    Sierra JM; Marco F; Ruiz J; Jiménez de Anta MT; Vila J
    Clin Microbiol Infect; 2002 Dec; 8(12):781-90. PubMed ID: 12519351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibacterial activity of a new tetracyclic quinolone, No. 5290, against norfloxacin- and ciprofloxacin-resistant strains of Staphylococcus aureus.
    Kotera Y; Inoue Y; Ohashi M; Ito K; Tsukamoto G
    Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2644-6. PubMed ID: 1666861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.
    Morrow BJ; Abbanat D; Baum EZ; Crespo-Carbone SM; Davies TA; He W; Shang W; Queenan AM; Lynch AS
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5512-21. PubMed ID: 21911562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
    Hidalgo M; Reyes J; Cárdenas AM; Díaz L; Rincón S; Vanegas N; Díaz PL; Castañeda E; Arias CA
    Biomedica; 2008 Jun; 28(2):284-94. PubMed ID: 18719726
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of in vitro activity of quinolone antibiotics and vancomycin against gentamicin- and methicillin-resistant Staphylococcus aureus by time-kill kinetic studies.
    Foster JK; Lentino JR; Strodtman R; DiVincenzo C
    Antimicrob Agents Chemother; 1986 Dec; 30(6):823-7. PubMed ID: 3643771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500.
    Entenza JM; Drugeon H; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1419-24. PubMed ID: 7492078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quinupristin-dalfopristin combined with beta-lactams for treatment of experimental endocarditis due to Staphylococcus aureus constitutively resistant to macrolide-lincosamide-streptogramin B antibiotics.
    Vouillamoz J; Entenza JM; Féger C; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1789-95. PubMed ID: 10858332
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.
    Okuda J; Okamoto S; Takahata M; Nishino T
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2288-93. PubMed ID: 1666495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus.
    Al-Nawas B; Shah PM
    J Antimicrob Chemother; 1998 Jun; 41(6):655-8. PubMed ID: 9687105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.
    Low DE; Muller M; Duncan CL; Willey BM; de Azavedo JC; McGeer A; Kreiswirth BN; Pong-Porter S; Bast DJ
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1119-21. PubMed ID: 11897603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Excellent activity of FK037, a novel parenteral broad-spectrum cephalosporin, against methicillin-resistant staphylococci.
    Mine Y; Watanabe Y; Sakamoto H; Hatano K; Kuno K; Kamimura T; Tawara S; Matsumoto Y; Matsumoto F; Kuwahara S
    J Antibiot (Tokyo); 1993 Jan; 46(1):99-119. PubMed ID: 8436564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.
    Chambers HF; Xiang Q; Liu ; Chow LL; Hackbarth C
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2742-6. PubMed ID: 10543757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.
    Zhao X; Eisner W; Perl-Rosenthal N; Kreiswirth B; Drlica K
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1023-7. PubMed ID: 12604537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.